Abaloparatide study finds higher bone density after knee replacement

A study published September 25 in JB & JS Open Access reports increased bone mineral density near the knee in patients with osteoporosis who received abaloparatide before and after knee replacement. The finding addresses a practical question in older adults’ care: whether strengthening bone around a replaced joint could help protect the benefits of surgery.

The research establishes a preliminary bone-density signal. It does not establish that the peptide treatment prevents fractures around implants, reduces repeat operations or prolongs independent mobility.

What the researchers measured

The prospective, open-label observational study enrolled 58 knee-replacement candidates aged 55 or older. Twenty-nine patients with clinical osteoporosis received abaloparatide, while 29 with osteopenia—less severe low bone density—and no prior fragility fracture formed an untreated comparison group.

The registered University of Wisconsin protocol followed participants for approximately 18 months, beginning before surgery and extending to 15 months afterward. Investigators used dual-energy X-ray absorptiometry, or DXA, to assess bone density, including two defined regions of the lower thighbone. They also collected questionnaires about joint function and other patient-reported outcomes.

The protocol explains why treatment was not randomly assigned: investigators considered withholding osteoporosis treatment from newly diagnosed patients inappropriate. Consequently, the comparison groups differed in the condition that determined treatment eligibility. That choice makes the study useful for exploring changes during clinical care, but limits causal conclusions.

A density signal with an unexpected comparison

According to the published abstract, changes in bone density at the two lower-thighbone measurement sites favored the abaloparatide group by 4.6% to 7.6% at six and 15 months after surgery. The reported comparisons were statistically significant.

However, the untreated group did not show a statistically significant decline in bone density at those sites. That finding complicates the original hypothesis that treatment would mitigate the postoperative bone loss described in earlier research.

An earlier conference report from this research appeared in 2025. The current development is the journal publication, rather than the first disclosure of the project or the initiation of treatment.

Why the comparison matters

The protocol explicitly recognized that comparing treated osteoporosis patients with untreated osteopenia patients was exploratory. These populations start with different bone health, so a difference in their subsequent trajectories cannot cleanly isolate the drug’s contribution.

There is also a distinction between measuring mineral density and demonstrating that a joint replacement lasts longer. The protocol’s rationale connects bone health with concern about fractures and implant support, but those clinical questions require evidence beyond an imaging change. Larger comparative studies with longer follow-up would be needed to determine whether this approach improves surgical outcomes.

An established drug, a narrower research question

Abaloparatide, marketed as Tymlos, is a synthetic 34-amino-acid peptide. Its prescribing information covers osteoporosis treatment in specified patients at high fracture risk; the new study does not establish a separate indication for protecting knee replacements.

The existing label also identifies risks, including orthostatic hypotension, elevated blood calcium and increased urinary calcium. A favorable bone-density finding therefore cannot be read as a complete assessment of benefits and harms in surgical patients.

For healthspan research, the relevant next step is connecting stronger bone measurements with outcomes that preserve function. This study supports investigating that connection, while leaving the effect on fractures, implant durability and long-term mobility unanswered.